Steve Brozak
Stock Analyst at WBB Securities
(2.89)
# 1,934
Out of 5,180 analysts
9
Total ratings
54.55%
Success rate
75.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Brozak
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMER Omeros | Reiterates: Strong Buy | $45 | $10.56 | +326.14% | 3 | Oct 15, 2025 | |
| CELU Celularity | Upgrades: Buy | $6 | $1.33 | +351.13% | 2 | Sep 9, 2025 | |
| MRKR Marker Therapeutics | Reiterates: Strong Buy | $13 | $1.30 | +861.54% | 1 | Apr 1, 2025 | |
| RDHL RedHill Biopharma | Downgrades: Buy | $17,000 → $16,000 | $0.74 | +2,147,839.32% | 3 | May 28, 2021 |
Omeros
Oct 15, 2025
Reiterates: Strong Buy
Price Target: $45
Current: $10.56
Upside: +326.14%
Celularity
Sep 9, 2025
Upgrades: Buy
Price Target: $6
Current: $1.33
Upside: +351.13%
Marker Therapeutics
Apr 1, 2025
Reiterates: Strong Buy
Price Target: $13
Current: $1.30
Upside: +861.54%
RedHill Biopharma
May 28, 2021
Downgrades: Buy
Price Target: $17,000 → $16,000
Current: $0.74
Upside: +2,147,839.32%